Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 2/20 | 0.43 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22577507 | 0.85 | HINT1 (0.51) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL26808492 | 0.85 | HINT1 (0.51) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL27216242 | 0.85 | HINT1 (0.51) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL25807955 | 0.85 | HINT1 (0.51) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL25813664 | 0.85 | HINT1 (0.51) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL16471919 | 0.85 | HINT1 (0.51) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL25613000 | 0.85 | HINT1 (0.49) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL20655347 | 0.84 | KDM4E (0.48) | HINT1HPGDNT5ETAS1R3TAS1R1 | |
| SCHEMBL24377170 | 0.83 | HINT1 (0.58) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL16844106 | 0.83 | HINT1 (0.49) | HINT1HPGDNT5EGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147467-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2021-05-20 | — | — | US | disclosed |
| US-10961270-B2 | Compounds and compositions for treating conditions associated with sting activity | INNATE TUMOR IMMUNITY, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200165288-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190016750-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | Innate Tumoir Immunity, Inc. (US) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961270-B2 | Compounds and compositions for treating conditions associated with sting activity | STING1, CGAS, IRF3 | HINT1 1249/4885HPGD 1546/4885NT5E 1878/4885 |
| US-20200165288-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HINT1 1249/4885HPGD 1546/4885NT5E 1878/4885 |
| US-20190016750-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | STING1, CGAS, IRF3 | HINT1 485/4885HPGD 517/4885NT5E 179/4885 |
| US-20210147467-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HINT1 1249/4885HPGD 1546/4885NT5E 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.